The corridor of land stretching between Oxford, Cambridge and London, long known as the “Golden Triangle” of British science, is undergoing a transformation that even its most optimistic advocates could not have predicted five years ago. The life sciences sector plan, published by the government in the summer of 2025, has catalysed an investment boom that is reshaping the physical, economic and intellectual landscape of the region, with £3 billion in combined public and private funding committed in the first twelve months alone.
The Golden Triangle is not a new phenomenon. Oxford and Cambridge have been centres of scientific inquiry for centuries, and London’s cluster of teaching hospitals, research institutes and pharmaceutical headquarters has been a global force in biomedical science since the post-war era. What is new is the scale and coordination of the investment, and the explicit policy intention to translate the region’s research excellence into commercial output, manufacturing capacity and high-skilled employment.
In Oxford, the expansion is visible in the cranes and construction hoardings that have become a familiar feature of the city’s eastern fringe. A new advanced therapy manufacturing centre, funded jointly by the government and a consortium of pharmaceutical companies, is nearing completion on the site of a former industrial estate. The facility, which will produce gene and cell therapies for clinical trials and, eventually, commercial supply, is expected to employ more than 400 scientists, engineers and technicians when it becomes fully operational in 2027.
Cambridge, meanwhile, is experiencing a similar surge. A major pharmaceutical company’s £600 million expansion of its research and development campus on the city’s biomedical corridor will add three new laboratory buildings, a clinical research unit and a collaborative innovation hub designed to bring together academic researchers, startup founders and industry scientists under one roof. The expansion is the largest single private investment in Cambridge’s life sciences sector since the establishment of the biomedical campus in the 1990s.
London’s contribution is more diffuse but no less significant. The capital’s network of teaching hospitals, including several world-renowned institutions, is being integrated into a coordinated clinical research infrastructure that will streamline the process of recruiting patients for trials, collecting data and translating research findings into clinical practice. A new life sciences data centre, located in the White City innovation district, will provide the computational infrastructure for genomic analysis, artificial intelligence-driven drug discovery and real-world evidence generation.
The economic impact on the region is substantial. The sector plan is estimated to have created more than 8,000 new jobs in the Golden Triangle over the past year, ranging from postdoctoral researchers and clinical trial coordinators to manufacturing technicians, data scientists and regulatory affairs specialists. The average salary in the life sciences sector is significantly above the regional median, and the multiplier effects on local economies — in housing, retail, transport and professional services — are considerable.
The property market has responded predictably. Commercial rents for laboratory and office space in Oxford and Cambridge have risen sharply, and several developers have announced plans for new life sciences parks on the peripheries of both cities. The pressure on housing is also acute, with key workers in the sector competing for accommodation in markets already constrained by green belt regulations, limited supply and high demand from the university and technology sectors.
